Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 3:26 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 1,574 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Period B Clear all

Conditions: Hypoxemic Respiratory Failure, Airway Obstruction
Interventions: nebulizer via in-line drug delivery maintaining high-flow nasal cannula oxygen, standard jet nebulization (SJN) with face mask; Device
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 2
States / cities: Los Angeles, California • Santa Monica, California

Conditions: Prostate Cancer, Recurrent Adenocarcinoma, Liver Cancer, Head and Neck Cancer
Interventions: MRI Simulator, Radiation Therapy; Device · Radiation
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2030
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Healthy
Interventions: ACY-1215; Drug
Lead sponsor: Acetylon Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Multiple Sclerosis, Long COVID, Long Covid19, Obese, Obesity, Obesity, Morbid, Acute Leukemia in Remission
Interventions: Liraglutide Pen Injector [Saxenda], Medication Diary; Drug · Other
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 40 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Malaria
Interventions: MAM01 1.5 mg/kg, Placebo, MAM01 5 mg/kg, MAM01 10 mg/kg, MAM01 40 mg/kg, MAM01 450 mg, Control, MAM01 600 mg, MAM01 900 mg; Biological · Other
Lead sponsor: Gates Medical Research Institute; Other
Eligibility: 18 Years to 50 Years
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Relapsed or Refractory Lymphoma
Interventions: HMPL-523, Rabeprazole; Drug
Lead sponsor: Hutchmed; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Durvalumab, Tremelimumab, Pemetrexed, Pembrolizumab, Carboplatin, Cisplatin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 47
States / cities: Beverly Hills, California • La Jolla, California • Los Alamitos, California + 40 more

Conditions: Healthy Volunteers; High Cholesterol
Interventions: NNC0385-0434 G, NNC0385-0434 F, NNC0385-0434 B; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 64 Years · Male only
Enrollment: 152 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 2
States / cities: Cypress, California • Los Angeles, California

Conditions: Respiratory Syncytial Virus
Interventions: mRNA-1345, Placebo; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 349 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 47
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Banning, California + 41 more

Conditions: Advanced Basal Cell Carcinoma
Interventions: Vismodegib 150 MG Oral Capsule; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Sickle Cell Disease
Interventions: GBT021601; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 3
States / cities: Miami, Florida • Atlanta, Georgia

Conditions: Bronchopulmonary Dysplasia
Interventions: Gastric Feeds, Jejunal Feeds; Procedure
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 0 Hours to 1 Year
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Well-Being, Psychological, Anxiety Depression
Interventions: PERSIST; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 25 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: OSA, Obstructive Sleep Apnea
Interventions: Period A, Period B, Period C; Drug
Lead sponsor: Apnimed; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 3
States / cities: Los Angeles, California • Boston, Massachusetts • St Louis, Missouri

Conditions: Healthy Male Adults, Food Effect in Healthy Volunteers
Interventions: AJ201; Drug
Lead sponsor: AnnJi Pharmaceutical Co., Ltd.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Los Alamitos, California

Conditions: Crohn's Disease
Interventions: GSK1605786 ChemoCentryx: formulation A, GSK1605786 GSK: formulation B, GSK1605786 GSK direct-fill: formulation C, GSK1605786 GSK modified-process: formulation D, GSK1605786 GSK tablet: formulation E; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Healthy Participants
Interventions: Vonoprazan, Lansoprazole; Drug
Lead sponsor: Phathom Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Diet Modification, HDL, Inflammation
Interventions: Mediterranean Diet, Fast food diet; Other
Lead sponsor: University of California, Davis; Other
Eligibility: 19 Years to 30 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Davis, California

Conditions: Advanced Solid Tumours
Interventions: AZD1775, MEDI4736; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2026
U.S. locations: 3
States / cities: Denver, Colorado • Sarasota, Florida • Nashville, Tennessee

Conditions: HER2-Positive Early Breast Cancer
Interventions: Pertuzumab and Trastuzumab Fixed-Dose Combination for Subcutaneous Administration (PH FDC SC), Pertuzumab IV, Trastuzumab IV; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 9
States / cities: Lakewood, Colorado • Peoria, Illinois • Wichita, Kansas + 5 more

Conditions: Crohn's Disease
Interventions: Filgotinib, Placebo; Drug · Other
Lead sponsor: Lakefront Biotherapeutics NV; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,372 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 101
States / cities: Dothan, Alabama • Sun City, Arizona • Coronado, California + 82 more

Conditions: Tardive Dyskinesia
Interventions: SD-809, Placebo; Drug
Lead sponsor: Auspex Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 343 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 44
States / cities: Tuscaloosa, Alabama • Anaheim, California • Glendale, California + 36 more

Conditions: Healthy
Interventions: FDC of Macitentan and Tadalafil, Macitentan, Tadalafil; Combination Product · Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma
Interventions: Loncastuximab Tesirine, Ibrutinib; Drug
Lead sponsor: ADC Therapeutics S.A.; Industry
Eligibility: 18 Years and older
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 12
States / cities: Orange, California • Redlands, California • Miami, Florida + 8 more

Search by objective public record fields.

In Line Aerosol Nebulization With High Flow

Jump: MR Simulation For Radiation Therapy Master Protocol

Alternative 10 mg/mL Liquid Formulation of ACY 1215 (Ricolinostat) in Healthy Subjects

Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory Issues

Safety, Tolerability, Pharmacokinetics and Protective Efficacy of MAM01 in Healthy Adults

HMPL-523 Food Effect and Proton Pump Inhibitor Study

A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS

A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation II

A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus

Adaptive Therapy of Vismodegib in Advanced Basal Cell Carcinoma

A Study to Evaluate GBT021601-012 Single Dose and Multiple Dose in Participants With Sickle Cell Disease (SCD)

Randomized Controlled Crossover Trial of Postpyloric Feedings to Improve Pulmonary Outcomes in High-risk Preterm Infants

Personal Resilience Skills to Improve Surgery Training

AD816 Crossover Study

A Study to Evaluate the Effect of Food on the Bioavailability of AJ201, and Safety, Tolerability, and Pharmacokinetics of AJ201 in Japanese and White Healthy Male Participants

A Study to Assess the Relative Bioavailability of Four New Formulations of GSK1605786 in Healthy Subjects

Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Vonoprazan and Lansoprazole in Healthy Participants

Effects of Short-term Diet on HDL Composition and Function

Safety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) Plus MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumours

A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast Cancer

Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's Disease

Reducing Involuntary Movements in Participants With Tardive Dyskinesia

A Study of Macitentan and Tadalafil as a Fixed Dose Combination and the Free Combination in Healthy Adult Participants

Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma